Caribou Biosciences Inc. Common Stock CRBU · Stock Open Caribou Biosciences Inc. Common Stock in new tab
Caribou Biosciences Inc. Common Stock Analysis (CRBU)
Is Caribou Biosciences Inc. Common Stock a good investment? Caribou Biosciences Inc. Common Stock (CRBU) is currently trading at 1.31 USD. Market analysts have a consensus price target of 11.86 USD. This suggests a potential upside from current levels.
Earnings Schedule: Caribou Biosciences Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.26.
Investor FAQ
Does Caribou Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Caribou Biosciences Inc. Common Stock?
Caribou Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.08.
Company Profile
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Community Discussion